Lineage Cell Therapeutics(US:LCTX)2025-05-13 20:10Financial Performance - Total revenues for Q1 2025 were $1.5 million, a net increase of $0.1 million compared to $1.4 million in Q1 2024, primarily driven by collaboration revenue from Roche[9] - Total revenues for Q1 2025 increased to $1,502,000, up 4% from $1,444,000 in Q1 2024[23] - Collaboration revenues rose to $1,270,000, a 7% increase compared to $1,187,000 in the same period last year[23] - Net loss attributable to Lineage for Q1 2025 was $4.1 million, or $0.02 per share, compared to a net loss of $6.5 million, or $0.04 per share, in Q1 2024[13] - Net loss attributable to Lineage decreased to $4,139,000 in Q1 2025 from $6,542,000 in Q1 2024, representing a 37% improvement[23] Operating Expenses - Operating expenses for Q1 2025 were $8.0 million, a decrease of $0.1 million from $8.1 million in Q1 2024[10] - R&D expenses for Q1 2025 were $3.1 million, an increase of $0.1 million compared to $3.0 million in Q1 2024, mainly due to preclinical programs[11] - Research and development expenses for Q1 2025 were $3,114,000, slightly up from $3,010,000 in Q1 2024[23] - General and administrative expenses decreased to $4,857,000 in Q1 2025 from $4,997,000 in Q1 2024, a reduction of 3%[23] - Net cash used in operating activities for Q1 2025 was $4,886,000, compared to $5,783,000 in Q1 2024, indicating a 15% improvement[25] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $47.9 million as of March 31, 2025, expected to support operations into Q1 2027[8] - Cash and cash equivalents at the end of Q1 2025 were $48,342,000, up from $44,122,000 at the end of Q1 2024, reflecting a 9% increase[25] - Total assets decreased to $111,753,000 in Q1 2025 from $113,218,000 in Q4 2024, a decline of 1%[21] - Total current liabilities decreased to $13,089,000 in Q1 2025 from $13,977,000 in Q4 2024, a reduction of 6%[21] - Total shareholders' equity increased to $77,655,000 in Q1 2025 from $77,012,000 in Q4 2024, a growth of 1%[21] Clinical Developments - The DOSED clinical study of OPC1 for spinal cord injury was initiated in February 2025, with UC San Diego Health as the first participating site[5] - The 36-month results of the RG6501 (OpRegen) Phase 1/2a clinical study will be presented on June 21, 2025, at Clinical Trials at the Summit 2025[6] - Lineage is advancing the OpRegen program and the GAlette Study, with ongoing collaboration with Roche and Genentech[7] - The 3rd Annual Spinal Cord Injury Investor Symposium is scheduled for June 27, 2025, aimed at discussing treatments for spinal cord injury[15] - Lineage's pipeline includes therapies for neurological and ophthalmic conditions, with a focus on OpRegen and OPC1[16]